Recent polling shows oncologists changing inclination in treatment for mHSPC based on tolerability profiles.

The median BMI of the cohort was 26.7 kg/m 2 (range, 17.9–55.2). Patients were classified into 3 main weight categories based ...

Findings from a recent clinical study (NCT05304793) show that cognitive behavioral therapy (CBT) can help patients with lung ...

RP1 and nivolumab combination achieved a 32.9% objective response rate and 15.0% complete response rate in advanced melanoma ...

The division of myelodysplastic syndromes (MDS) into low-risk and high-risk categories guides prognosis and treatment, with patients who have lower-risk disease typically receivin ...

Findings from a prospective phase 2 clinical trial show that isatuximab (Sarclisa), an anti-CD38 monoclonal antibody, is an effective and well-tolerated treatment for patients with relapsed and/or ...

Topline results from the phase 3 HERIZON-GEA-01 trial show that the HER2-targeted bispecific antibody zanidatamab-hrii ...

Visugromab combined with nivolumab showed a median duration of response exceeding two years in refractory NSCLC, UC, and HCC patients. GDF-15 is a therapeutic target and immune escape mechanism, ...

The FDA has granted an accelerated approval to sevabertinib (Hyrnuo) for the treatment of adult patients with previously ...

Peers & Perspectives® in Oncology delivers exclusive coverage of virtual and in-person live events held by Targeted Oncology and Healthcare Research & Analytics®, thought leader collaborations, and ...

Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.

The FDA has granted full approval to tarlatamab-dlle (Imdelltra) for the treatment of adult patients with extensive stage ...